The authors of the above manuscript would like to issue a correction notice as below.

Recently we reviewed our own manuscript entitled “Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register”, originally published in *Rheumatology* in January 2010, and have identified an error in the calculation of incident rates and incident rate ratios presented in Table 5. We were able to retrieve the dataset and original statistical files used to generate these results and have identified a programming error. Luckily, the results do not change significantly and the conclusions of the paper are unchanged.

We also identified a small error in the text: the number of skin cancers in our two groups were transposed, and this must have been missed at the point of proof approval. We have subsequently reviewed all of the data presented in this paper and are confident that the rest of the data are accurate.

### Table 5 SAEs in PsA cases and seronegative RA control cohorts

| SAEs (MedDRA SOC)                        | Control (n = 1115) | All anti-TNF (n = 596) |
|------------------------------------------|--------------------|------------------------|
| Total no. of SAEs                        | 624                | 211                    |
| Total person-years of FUP (SAEs)         | 3409.9             | 1776.2                 |
| Total IRRs (95% CI)                      | Ref                | 1.0 (0.8, 1.3)         |
| Infections, n                            | 137                | 53                     |
| Rate/1000 person-years (95% CI)          | 40.2 (33.7, 47.5)  | 29.8 (22.4, 39.0)      |
| IRRs (95% CI)                            | Ref                | 1.1 (0.7, 1.6)         |
| Neoplasms, n                             | 67                 | 14                     |
| Rate/1000 person-years (95% CI)          | 19.6 (15.2, 25.0)  | 7.9 (4.3, 13.2)        |
| IRRs (95% CI)                            | Ref                | 0.9 (0.5, 1.6)         |
| Cardiac disorders, n                     | 56                 | 16                     |
| Rate/1000 person-years (95% CI)          | 16.4 (12.4, 21.3)  | 9.0 (5.1, 14.6)        |
| IRRs (95% CI)                            | Ref                | 0.9 (0.5, 1.8)         |
| GIT disorders, n                         | 31                 | 14                     |
| Rate/1000 person-years (95% CI)          | 9.1 (6.2, 12.9)    | 7.9 (4.3, 13.2)        |
| IRRs (95% CI)                            | Ref                | 1.4 (0.6, 3.1)         |
| Musculoskeletal and CTDs, n              | 48                 | 12                     |
| Rate/1000 person-years (95% CI)          | 14.1 (10.4, 18.7)  | 6.8 (3.5, 11.8)        |
| IRRs (95% CI)                            | Ref                | 1.0 (0.5, 2.1)         |
| Nervous system disorders, n              | 43                 | 13                     |
| Rate/1000 person-years (95% CI)          | 12.6 (9.1, 17.0)   | 7.3 (3.9, 12.5)        |
| IRRs (95% CI)                            | Ref                | 0.6 (0.2, 2.0)         |

1School of Pharmacy and Pharmaceutical Sciences and 2Arthritis Research Campaign (ARC) Epidemiology Unit, University of Manchester, Manchester, UK.

© The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The last sentence of the Results part of the abstract should read:

Over 1776.2 person-years of follow-up (median 3.07 per person), the IRR of SAEs compared with controls was not increased (1.0; 0.8, 1.3).

The penultimate sentence in the Results section should read:

There were 29 reports of skin cancer in total, including 17 basal cell cancers (13 in controls, 4 in anti-TNF), 8 non-melanoma skin cancers not otherwise specified (6 in controls, 2 in anti-TNF) and 4 melanomas (2 in each group).

Table 5 should read as follows above: